Evidence map›Paper›PMID 25700355›Full record

ArticleOncology research2014

TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway.

Weitao Yao, Xin Wang, Qiqing Cai, Songtao Gao, Jiaqiang Wang, Peng Zhang

Open access · hybridAbstract read
In one paragraph

Article in Oncology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. [RHPN2 is highly expressed in osteosarcoma cells to promote cell proliferation and migration and inhibit apoptosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Expression and Association of Tumor Necrosis Factor Receptor Associated Factor 4 (TRAF4) in Esophageal Squamous Cell Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Weitao YaoDepartment of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalZhengzhouChina.
Xin WangDepartment of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalZhengzhouChina.
Qiqing CaiDepartment of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalZhengzhouChina.
Songtao GaoDepartment of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalZhengzhouChina.
Jiaqiang WangDepartment of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalZhengzhouChina.
Peng ZhangDepartment of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalZhengzhouChina.
Henan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TRAF4, or tumor necrosis factor receptor-associated factor 4, is overexpressed in several cancers, suggesting a specific role in cancer progression. However, its functions in osteosarcoma are unclear. This study aimed to explore the expression of TRAF4 in osteosarcoma tissues and cells, the correlation of TRAF4 to clinical pathology of osteosarcoma, as well as the role and mechanism of TRAF4 in osteosarcoma metastasis. The protein expression levels of TRAF4 in osteosarcoma tissues and three osteosarcoma cell lines, MG-63, HOS, and U2OS, were assessed. Constructed TRAF4 overexpression vectors and established TRAF4 overexpression of the U2OS cell line. Cell proliferation, cell invasion, protein levels, and TRAF4 phosphorylations were assessed following TRAF4 transfection, as well as the effects of TRAF4 siRNA on cell proliferation and invasion. The results show that TRAF4 protein levels in osteosarcoma tissues were significantly higher than that in normal bone tissues. Importantly, an obvious upregulation of TRAF4 was found in carcinoma tissues from patients with lung metastasis compared with patients without lung metastasis. Consistently, a similar increase in TRAF4 mRNA and protein was also demonstrated in the osteosarcoma cell lines MG-63, HOS, and U2OS compared to normal bone cells, hFOB1.19. When TRAF4 was overexpressed in U2OS cells, cell proliferation was significantly enhanced, accompanied by an increase in Ki67 expression and colony formation. Compared with the control and vector-treated groups, TRAF4 transfection increased the invasion potential of U2OS cells (p < 0.05). Interestingly, TRAF4 transfection significantly enhanced the phosphorylation of Akt. After blocking Akt with its specific siRNA, TRAF4-induced cell proliferation and invasion were dramatically attenuated. In summary, our findings demonstrated that TRAF4 enhances osteosarcoma cell proliferation and invasion partially by the Akt pathway. This work suggests that TRAF4 might be an important target in osteosarcoma.

Indexed as

Bone and BonesBone NeoplasmsCarcinogenesisCell Line, TumorCell ProliferationHumansNeoplasm InvasivenessNeoplasm MetastasisOncogene Protein v-aktOsteosarcomaPhosphorylationRNA, Small InterferingSignal TransductionTNF Receptor-Associated Factor 4TransgenesOncogene Protein v-aktRNA, Small InterferingTNF Receptor-Associated Factor 4

Identifiers

PMID25700355
PMCPMC7592778
OpenAlexW2329120269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.